Recon: Opioid makers score a win in California trial; Pfizer sees 2021, 2022 COVID vaccine sales to hit $65B

• Opioid Makers Win Major Victory in California Trial (NYTimes) (Reuters) (STAT)
• Pfizer expects 2021, 2022 COVID-19 vaccine sales to total at least $65 bln (Reuters) (FT)
• U.S. CDC advisers to vote on COVID-19 vaccine in young children (Reuters)
• FDA extends review of J&J, Legend's cell therapy for multiple myeloma (BioPharmaDive)
• Progressive Democrats scramble to secure curbs on drug prices (FT) (STAT)
• Manchin Raises Doubts on Safety Net Bill, Complicating Path to Quick Vote (NYTimes 1, 2)
• White House says 15 mln COVID-19 shots will roll out to children by next week (Reuters)
• U.S. buys more doses of Lilly's COVID-19 treatment for $1.29 bln (Reuters)
• Moderna, making billions from its vaccine, bets on a genome-editing startup (STAT) (Endpoints)
• Amylyx asks FDA to approve ALS drug, while also preparing late-stage study (BioPharmaDive)

• EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly (EMA)
• AstraZeneca increases COVID-19 vaccine supply to Thailand after row (Reuters)
• Novavax COVID-19 vaccine gets first authorization; expects more within weeks, CEO says (Reuters)
• Novartis enlists transatlantic startup to discover new protein degraders in $1.3B+ deal (Endpoints)

• ‘Not Quite on Board’: Parents Proving a Tough Sell on Covid Vax for Teens (KHN)
• Bahrain approves Pfizer COVID vaccine for children aged 5-11 (Reuters)

• Could Robert Califf’s ties to tech complicate his FDA nomination? (STAT)
• Pfizer reveals delays across the board for its clinical gene therapy programs (Endpoints)
• As anti-inflammatory space heats up, Pfizer spins JAK, TYK2 drugs into new startup (Endpoints)
• Clene's mid-stage ALS drug hits a brick wall, but can an 'efficacy signal' save the day? (Endpoints)
• US FDA Chief Scientist Hinton’s Departure Leaves Vacancy Atop Makena Decision Tree (Pink Sheet)
• Fresh off Kite and BeiGene deals, Shoreline ups the ante with a hefty crossover. But the biotech insists it's in no rush (Endpoints)
• AbbVie, Janssen, Novartis, Pfizer and UCB to jointly advance 'digital' endpoint for atopic dermatitis (Endpoints)
• Perceptive steers LianBio's globally connected China strategy to $325M IPO (Endpoints)

• Safety of Endologix endovascular graft device center of FDA panel review (MedtechDive)
• GV-backed Cambridge Epigenetix lines up $88M to roll out genetic sequencing technology (Fierce)
• Can Regional Trade Pact Force Change On Chinese Local Medtech Procurement? (MedtechInsight)

• Federal Court Orders Tampa Pharmacy to Close in Case Alleging Unlawful Opioid Distribution (DOJ)